2024 - Cracking Cirrhosis: Complexity of Chronic Liver Disease and Insights for Drug Development
Date2024-10-15
Deadline2024-10-15
VenueONLINE-VIRTUAL, USA - United States
KeywordsLife Sciences; Pharmaceutical; Drug Discovery & Development
Topics/Call fo Papers
Chronic liver disease is complex. The causes are multifactorial, disease progression is slow and heterogeneous, and the pathophysiology is complicated and still not entirely understood. This has made drug development challenging, and there are still no approved treatments targeting cirrhosis.
Currently, treatment options are limited to addressing the complications of cirrhosis. But there is a lot of ongoing research activity and exciting progress being made in the field of chronic liver disease.
Join our expert speakers as they walk through the complexity of chronic liver disease and the resulting cirrhosis. This webinar will unpack the drivers of liver disease and its progression via inflammation and fibrosis, as well as the implications for drug development and patient selection. It will also cover some of the biomarkers and other tools, such as magnetic resonance imaging (MRI) and positron emission tomography (PET) alone and in combination with other biomarkers, that can help further our disease understanding and provide valuable insights within drug development.
Join this webinar to learn about chronic liver disease biology and pathophysiology, drug development in this space, and to hear our speakers discuss their perspectives of the future for treatment of chronic liver diseases.
Keywords: Drug Development, Cirrhosis, Liver, Clinical Research, Liver Disease, Biomarkers, NASH, NAFLD, Therapeutic Areas, Fatty Liver, Non-Alcoholic Fatty Liver Disease, MASH
Currently, treatment options are limited to addressing the complications of cirrhosis. But there is a lot of ongoing research activity and exciting progress being made in the field of chronic liver disease.
Join our expert speakers as they walk through the complexity of chronic liver disease and the resulting cirrhosis. This webinar will unpack the drivers of liver disease and its progression via inflammation and fibrosis, as well as the implications for drug development and patient selection. It will also cover some of the biomarkers and other tools, such as magnetic resonance imaging (MRI) and positron emission tomography (PET) alone and in combination with other biomarkers, that can help further our disease understanding and provide valuable insights within drug development.
Join this webinar to learn about chronic liver disease biology and pathophysiology, drug development in this space, and to hear our speakers discuss their perspectives of the future for treatment of chronic liver diseases.
Keywords: Drug Development, Cirrhosis, Liver, Clinical Research, Liver Disease, Biomarkers, NASH, NAFLD, Therapeutic Areas, Fatty Liver, Non-Alcoholic Fatty Liver Disease, MASH
Other CFPs
- Harnessing Real-World Data for Strategic Partner Targeting and Early Patient Identification in Precision Medicine
- Improving Patient Experience: Optimizing Patient Payment Systems Through Collaboration
- Innovative Approaches in Metabolic Dysfunction-Associated Steatohepatitis Clinical Research
- Navigating Complexity: Tailoring Cell-Based Bioassays for Advanced Therapeutics
- PROTACs: Breaking Boundaries in Drug Discovery
Last modified: 2024-09-17 05:15:29